NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

XELOX for Metastatic Breast Cancer

NCT00204776

CompletedPhase 2

Sponsor: University of Wisconsin, Madison

Conditions: Metastatic Breast Cancer

Interventions: Capecitabine and Oxaliplatin

Countries: United States

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* preserved organ function
* good performance status
* no more than one prior therapy
* no active brain metastasis

Exclusion Criteria:

* No prior capecitabine or oxaliplatin
* no con-current therapy

Locations (1)

Madison, Wisconsin, United States